Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends aripiprazole

NICE's FAD recommends the use of Bristol-Myers Squibb's atypical anti-psychotic drug Abilify (aripiprazole) as an option for the treatment of adolescent schizophrenia

The National Institute for Health and Clinical Excellence's (NICE) Final Appraisal Determination (FAD) has recommended the use of Abilify (aripiprazole) as an option for the treatment of schizophrenia in people aged 15 to 17 years who are intolerant of risperidone, or for whom risperidone is contraindicated, or whose schizophrenia has not been adequately controlled with risperidone.

Aripiprazole received its first EU approval in 2004. In the UK it is the only commonly-used atypical anti-psychotic licensed for the treatment of adolescent schizophrenia and the first to be appraised by NICE.

The announcement of NICE's forthcoming guidance, which will offer patients in the UK access to a cost-effective treatment for their condition, has been welcomed by patient groups.

According to Marjorie Wallace, CBE, chief executive of mental health charity, SANE: "Everyone's biochemistry differs and the more we can find a choice of medications to target individual needs, with side-effects that can be tolerated, the more we can help people to manage their condition."

"This is particularly important in teenagers: schizophrenia often strikes at this time and it is vital to find effective treatment and prevent relapse, With better medications and therapies, the lives of young people with schizophrenia can be greatly improved," Wallace said.

1st December 2010

From: Healthcare

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...